Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey - 14/12/17
, Shaloo Gupta, MSc b, Caroline Amand, PhD a, Abhijit Gadkari, PhD c, Puneet Mahajan, PhD d, Joel M. Gelfand, MD eAbstract |
Background |
Given its public health impact, there is need for broad and representative data on the humanistic burden of atopic dermatitis (AD).
Objective |
To establish the humanistic burden of AD in US adults.
Methods |
Data were from the 2013 US National Health and Wellness Survey; AD self-reports were propensity-matched with non-AD controls and with psoriasis controls. Bivariate analyses were conducted on burden outcomes between the AD and control groups.
Results |
Demographics and baseline characteristics were comparable between matched groups. Subjects with AD (n = 349) versus non-AD controls (n = 698) had significantly higher rates of anxiety, depression, and sleep disorders (29.8%, 31.2%, and 33.2% vs 16.1%, 17.3%, and 19.2%, respectively [all P < .001]); a lower Short Form-36 v2 mental component summary score (44.5 vs 48.0, respectively [P < .001]); a lower physical component summary score (47.6 vs 49.5, respectively [P = .004]), and lower health utilities (0.67 vs 0.72, respectively [P < .001]) in addition to a higher work absenteeism rate (9.9% vs 3.6%, respectively [P < .001]) and activity impairment rate (33.6% vs 25.2%, respectively [P < .001]). Subjects with AD and psoriasis controls (n = 260 each) showed similar impairment in health-related quality of life and productivity.
Limitations |
Data were self-reported.
Conclusion |
AD is associated with a substantial humanistic burden that is similar in magnitude to that of psoriasis, which is also recognized for its debilitating symptoms, indicating the need for more effective treatments for AD.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, burden of dermatitis, burden of disease, eczema, mental health, mood disorder, patient-reported outcomes, productivity, quality of life, sleep disorder
Abbreviations used : AD, HRQoL, NHWS, MCS, OR, PCS, SF-6D, SF-36v2, WPAI
Plan
| Supported by Sanofi and Regeneron Pharmaceuticals, Inc. |
|
| Disclosure: Drs Eckert, Amand, and Mahajan are employees of and stockholders in Sanofi. Ms Gupta works for a company that received research funding from Sanofi/Regeneron Pharmaceuticals, Inc., for the current study. Dr Gadkari is an employee of and stockholder in Regeneron Pharmaceuticals, Inc. Dr Gelfand is an employee of the University of Pennsylvania Perelman School of Medicine, which has received research funding from Sanofi/Regeneron Pharmaceuticals, Inc. In the previous 12 months, Dr Gelfand served as a consultant for Abbvie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Valeant, and Pfizer Inc., receiving honoraria; he receives research grants (to the trustees of the University of Pennsylvania) from Abbvie, Eli Lilly, Janssen, Novartis Corp, Regeneron, Sanofi, and Pfizer Inc.; and he has received payment for CME work related to psoriasis. Dr Gelfand is also a co–patent holder of Resiquimod for the treatment of cutaneous T-cell lymphoma. |
|
| Reprints not available from the authors. |
Vol 77 - N° 2
P. 274 - août 2017 Retour au numéro
Article précédent
- Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa
- Mohammed Dany, Dirk Elston
- Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis
- Jacob P. Thyssen, Peter B. Toft, Anne-Sofie Halling-Overgaard, Gunnar H. Gislason, Lone Skov, Alexander Egeberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?